Lipella Pharmaceuticals Inc Quick Ratio (LIPO) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lipella Pharmaceuticals Inc   (LIPO)

Lipella Pharmaceuticals Inc 's Quick Ratio

LIPO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2025, Quick Ratio deteriorated to 2.89 below Lipella Pharmaceuticals Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 227 other companies have achieved higher Quick Ratio than Lipella Pharmaceuticals Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 630 to 780.

Explain Quick Ratio?
How much Cash & cash equivalents LIPO´s has?
What are LIPO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LIPO Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change 16.96 % 144.6 % 17.85 % 62.45 % 0.1 %
Y / Y Cash & cash equivalent Change 37.09 % 134.46 % 100.68 % -33.67 % -43.82 %
Quick Ratio MRQ 2.89 3.72 6.5 3.49 2.46
LIPO's Total Ranking # 780 # 630 # 436 # 762 # 804
Seq. Current Liabilities Change -13.99 % 14.83 % 3.89 % 13.99 % 79.87 %
Seq. Cash & cash equivalent Change -33.29 % -34.16 % 93.38 % 61.4 % 14.09 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 228
Healthcare Sector # 377
Overall Market # 780


Quick Ratio Statistics
High Average Low
10.42 5.01 2.46
(Jun 30 2023)   (Sep 30 2024)




Financial Statements
Lipella Pharmaceuticals Inc 's Current Liabilities $ 1 Millions Visit LIPO's Balance sheet
Lipella Pharmaceuticals Inc 's Cash & cash equivalent $ 2 Millions Visit LIPO's Balance sheet
Source of LIPO's Sales Visit LIPO's Sales by Geography


Cumulative Lipella Pharmaceuticals Inc 's Quick Ratio

LIPO's Quick Ratio for the trailling 12 Months

LIPO Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 48.77 % 43.61 % 19.4 % 4.22 % -34.68 %
Y / Y Cash & cash equivalent TTM Growth 39.15 % 17.23 % -18.06 % -46.79 % -45.86 %
Quick Ratio TTM 4.14 4.1 4.2 3.36 4.43
Total Ranking TTM # 2862 # 2933 # 3068 # 3144 # 3174
Seq. Current Liabilities TTM Growth 3.62 % 20.72 % 4.85 % 13.43 % 0.03 %
Seq. Cash & cash equivalent TTM Growth 4.76 % 17.82 % 31.03 % -13.97 % -11.74 %

Quick ratio ranking by company, industry and sector >> Back to LIPO Financial Strength Comparisons >> Go to Compare LIPO Quick Ratio to its Competitors

On the trailing twelve months basis LIPO Cash & cash equivalent grew by 37.09 % in Q3 2025 year on year, faster than Current Liabilities, this led to increase in in Lipella Pharmaceuticals Inc 's Quick Ratio to 4.14, Quick Ratio remained below LIPO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 403 other companies have achieved higher Quick Ratio than Lipella Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 2862, from total ranking during the twelve months ending second quarter 2025 at 2933.

Explain Quick Ratio?
How much Cash & cash equivalents LIPO´s has?
What are LIPO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 404
Healthcare Sector # 825
Within the Market # 2862


trailing twelve months Quick Ratio Statistics
High Average Low
6.58 4.42 2.75
(Dec 31 2023)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Cytokinetics Incorporated  7.92 $ 962.535  Millions$ 121.497  Millions
Olema Pharmaceuticals Inc   7.90 $ 328.960  Millions$ 41.655  Millions
Moonlake Immunotherapeutics  7.87 $ 380.479  Millions$ 48.368  Millions
Hoth Therapeutics Inc   7.85 $ 7.848  Millions$ 0.999  Millions
Milestone Pharmaceuticals Inc   7.85 $ 82.585  Millions$ 10.524  Millions
Lipocine Inc   7.84 $ 15.131  Millions$ 1.931  Millions
Amarin Corp Plcuk  7.81 $ 286.888  Millions$ 36.712  Millions
Actinium Pharmaceuticals Inc  7.81 $ 53.391  Millions$ 6.834  Millions
Abcellera Biologics Inc   7.77 $ 412.513  Millions$ 53.117  Millions
Anixa Biosciences Inc   7.71 $ 15.174  Millions$ 1.967  Millions
Galmed Pharmaceuticals Ltd   7.71 $ 19.051  Millions$ 2.472  Millions
Coya Therapeutics Inc   7.67 $ 28.130  Millions$ 3.667  Millions
Zevra Therapeutics Inc   7.64 $ 199.509  Millions$ 26.112  Millions
Compass Pathways Plc  7.55 $ 186.316  Millions$ 24.692  Millions
Kiora Pharmaceuticals Inc   7.51 $ 19.375  Millions$ 2.580  Millions
Zentalis Pharmaceuticals Inc   7.49 $ 278.291  Millions$ 37.168  Millions
Galera Therapeutics Inc   7.48 $ 4.473  Millions$ 0.598  Millions
Savara Inc   7.42 $ 124.386  Millions$ 16.757  Millions
Ocular Therapeutix Inc   7.41 $ 344.772  Millions$ 46.532  Millions
Evommune Inc   7.30 $ 76.062  Millions$ 10.416  Millions
Annovis Bio Inc   7.24 $ 15.286  Millions$ 2.112  Millions
Forte Biosciences Inc   7.19 $ 93.414  Millions$ 12.992  Millions
Rocket Pharmaceuticals Inc   7.15 $ 222.758  Millions$ 31.170  Millions
Chemomab Therapeutics Ltd   7.01 $ 10.366  Millions$ 1.478  Millions
Ataibeckley Inc   6.93 $ 114.606  Millions$ 16.544  Millions
Anaptysbio Inc   6.90 $ 248.956  Millions$ 36.064  Millions
Barinthus Biotherapeutics Plc  6.88 $ 74.272  Millions$ 10.798  Millions
Kalvista Pharmaceuticals Inc   6.86 $ 309.158  Millions$ 45.069  Millions
Revelation Biosciences Inc   6.85 $ 12.708  Millions$ 1.854  Millions
Kezar Life Sciences Inc   6.74 $ 90.216  Millions$ 13.376  Millions

Date modified: 2026-06-22T16:30:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.